Phaseline

Companies › United Therapeutics

United Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 2 Phase 1, 2 Phase 4, 1 Phase 3; Genitourinary, Cardiovascular, Respiratory; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Treprostinil
Prostanoid IP receptor agonist
PTGIRPhase 4Pulmonary Arterial Hypertension; Progressive Pulmonary FibrosisNov 2027
10 GE Xenokidney
Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT
GGTA1, CMAH, BHMT, PERVPhase 1ESRD (End-Stage Renal Disease)Oct 2028
GGTA1 KO Thymokidney
Porcine kidney with GGTA1 gene knockout (xenotransplant) combined with thymic tissue autog
GGTA1Phase 1ESRD (End-Stage Renal Disease)Nov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05943535TreprostinilPhase 3Progressive Pulmonary FibrosisRespiratoryNov 2027
NCT05203510TreprostinilPhase 4Pulmonary Arterial HypertensionCardiovascularApr 2028
NCT05203510TreprostinilPhase 4Pulmonary Arterial HypertensionCardiovascularApr 2028
NCT0687856010 GE XenokidneyPhase 1ESRD (End-Stage Renal Disease)GenitourinaryOct 2028
NCT07224763GGTA1 KO ThymokidneyPhase 1ESRD (End-Stage Renal Disease)GenitourinaryNov 2029

From the company's SEC filings

Cash and short-term investments of $2.1bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GGTA1 (2) CMAH (1) BHMT (1) PERV (1) PTGIR (1)

Companies with the same targets

Xeno Holdings (US), LLC dba ChoironeX Prescient Therapeutics Insmed Johnson & Johnson (Janssen) Liquidia Technologies

Companies built like this

Travere Therapeutics Neurocrine Switzerland TolerogenixX Innovacell Iperboreal Pharma Srl

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.